XNYS
BHC
Market cap2.26bUSD
Oct 08, Last price
6.04USD
1D
-1.79%
1Q
26.36%
Jan 2017
-58.40%
Name
Bausch Health Companies Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bausch Health Companies Inc. is a global healthcare enterprise dedicated to the creation, production, and sale of a diverse array of pharmaceutical, medical device, and over-the-counter items. Its primary therapeutic focus areas include eye health, digestive system issues, and dermatological conditions. The company's operations are strategically organized into five key divisions: Bausch + Lomb, which specializes in vision care, surgical solutions, and ophthalmic pharmaceuticals; Salix, concentrating on gastroenterology products within the United States; International Rx, offering a broad portfolio encompassing Solta products, branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across numerous international markets in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East; Ortho Dermatologics, providing dermatological products in the U.S. and Solta medical aesthetic devices globally; and Diversified Products, covering pharmaceutical products in neurology and other therapeutic classes, alongside generic and dentistry items in the United States. Previously known as Valeant Pharmaceuticals International, Inc., the company adopted its current name in July 2018 and maintains its headquarters in Laval, Canada.
Related entities
Subsidiaries (4)
BAUSCH & LOMB INDIA PRIVATE LIMITED
Bausch & Lomb Incorporated
Bausch+Lomb Netherlands B.V.
Key people
John Paulson
Independent Non-Executive Chairman of the Board · since 2022
Jean-Jacques Charhon
Executive Vice President, Chief Financial Officer · since 2025
Aimee Lenar
Executive Vice President, US Pharma · since 2024
John Barresi
Senior Vice President, Chief Accounting Officer, Controller · since 2024
Seana Carson
Executive Vice President, General Counsel · since 2022
Steven Lee
Senior Vice President, Controller, Chief Accounting Officer · since 2025
Thomas Appio
Chief Executive Officer, Director · since 2022
Michael Goettler
Director · since 2025
Sandra Leung
Director · since 2025
Independent Director · since 2024
Independent Director · since 2016
Independent Director · since 2024
Steven Miller
Independent Director · since 2021
Richard Mulligan
Independent Director · since 2022
John Paulson
Independent Non-Executive Chairman of the Board · since 2022
Robert Power
Independent Director · since 2008
Amy Wechsler
Independent Director · since 2016
Legal address
1055 WEST HASTINGS STREET
SUITE 1700
Vancouver, BC V6E 2E9
CA
SUITE 1700
Vancouver, BC V6E 2E9
CA
Headquarters
2150 Saint Elzéar Boulevard West
Laval, QC H7L 4A8
CA
Laval, QC H7L 4A8
CA
Previous name
BIOVAIL CORPORATION
Previous name
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||